(NASDAQ: SLN) Silence Therapeutics's forecast annual revenue growth rate of 6.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Silence Therapeutics's revenue in 2024 is $32,120,253.On average, 3 Wall Street analysts forecast SLN's revenue for 2024 to be $3,710,758,819, with the lowest SLN revenue forecast at $2,920,069,955, and the highest SLN revenue forecast at $4,236,894,338. On average, 3 Wall Street analysts forecast SLN's revenue for 2025 to be $5,755,283,176, with the lowest SLN revenue forecast at $1,110,030,662, and the highest SLN revenue forecast at $13,130,212,804.
In 2026, SLN is forecast to generate $3,704,459,930 in revenue, with the lowest revenue forecast at $3,025,843,754 and the highest revenue forecast at $4,383,076,106.